Literature DB >> 9330981

Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies.

D W Dickson1.   

Abstract

Alzheimer's disease (AD) is the most common cause of primary progressive dementia. It is defined by its pathological features, because the clinical syndrome of dementia lacks specificity. Although the brain in AD has many structural alterations, the two cardinal pathological features and sine qua non of AD are senile plaques and neurofibrillary degeneration. The latter takes the form of neurofibrillary tangles composed of paired helical filaments, as well as degenerating neurites within the neuropil ("neuropil threads") and within a diagnostically significant subset of SP, referred to as "neuritic plaques." All SP contain amyloid, but not all have pair helical filament-type neurites. The presence of even a small number of plaques with paired helical filament-type neurites in the neocortex is associated with cognitive impairment, and this lesion may be the most specific histopathological feature of AD. Although these observations suggest that the major difference between SP in aging and AD relate to differences in neuritic degeneration, more recent studies have also indicated that amyloid deposits are biochemically heterogenous and that amyloid deposits in aging may be different from those in AD. As more specific markers become available for recognizing AD-specific structural lesions, refined neuropathological diagnostic criteria will evolve. In the meantime, a practical neuropathological approach to the diagnosis of AD requires both widespread neocortical SP and an advanced stage of neurofibrillary degeneration. Using these criteria, it is very unlikely that AD will be diagnosed in an individual who was not demented in life. The rationale for adopting this conservative approach is that our knowledge is incomplete with respect to fundamental differences between the lesions in aging and AD.

Entities:  

Mesh:

Year:  1997        PMID: 9330981     DOI: 10.1016/s0197-4580(97)00065-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  49 in total

1.  Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.

Authors:  B Kaltschmidt; M Uherek; H Wellmann; B Volk; C Kaltschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  In vivo amyloid imaging in Alzheimer's disease.

Authors:  H I Sair; P M Doraiswamy; J R Petrella
Journal:  Neuroradiology       Date:  2004-01-23       Impact factor: 2.804

Review 3.  In vivo brain imaging of tangle burden in humans.

Authors:  Gary W Small; Eric D Agdeppa; Vladimir Kepe; Nagichettiar Satyamurthy; Sung-Cheng Huang; Jorge R Barrio
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

Review 4.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

5.  Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.

Authors:  Ji Zhang; Suqing Wang; Wei Huang; David A Bennett; Dennis W Dickson; Dengshun Wang; Rui Wang
Journal:  Mol Neurobiol       Date:  2015-09-19       Impact factor: 5.590

6.  SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.

Authors:  Laurel O Sillerud; Nathan O Solberg; Ryan Chamberlain; Robert A Orlando; John E Heidrich; David C Brown; Christina I Brady; Thomas A Vander Jagt; Michael Garwood; David L Vander Jagt
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease.

Authors:  Mark Kilgore; Courtney A Miller; Daniel M Fass; Krista M Hennig; Stephen J Haggarty; J David Sweatt; Gavin Rumbaugh
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

8.  Contribution of vascular pathology to the clinical expression of dementia.

Authors:  Dorothea Strozyk; Dennis W Dickson; Richard B Lipton; Mindy Katz; Carol A Derby; Sunhee Lee; Cuiling Wang; Joe Verghese
Journal:  Neurobiol Aging       Date:  2008-11-08       Impact factor: 4.673

Review 9.  Buccal Mucosa Biomarkers in Alzheimer's Disease.

Authors:  Antigoni Avramouli; Panayiotis Vlamos
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe.

Authors:  Hye-Yeong Kim; Urmi Sengupta; Pin Shao; Marcos J Guerrero-Muñoz; Rakez Kayed; Mingfeng Bai
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.